STAAR Surgical to Report First Quarter Results on May 4, 2022

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) will announce its financial results for Q1 ending April 1, 2022, on May 4, 2022, post-market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Participants can join by dialing 844-200-6205 (domestic) or 929-526-1599 (international). A replay of the call will be available for seven days after the event. STAAR specializes in implantable lenses and has successfully implanted over 1,000,000 Visian ICLs across more than 75 countries.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close.

STAAR will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 592913), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 295785) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005127/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical release its financial results?

STAAR Surgical will release its financial results for Q1 on May 4, 2022, after market close.

What time is the STAAR Surgical conference call?

The conference call for STAAR Surgical will take place on May 4, 2022, at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

How can I access the STAAR Surgical conference call?

To access the STAAR Surgical conference call, dial 844-200-6205 for domestic calls or 929-526-1599 for international calls.

What product line does STAAR Surgical focus on?

STAAR Surgical focuses on implantable lenses, including the EVO Visian ICL product line.

How many Visian ICLs has STAAR Surgical implanted?

STAAR Surgical has implanted over 1,000,000 Visian ICLs worldwide.

Where is STAAR Surgical headquartered?

STAAR Surgical is headquartered in Lake Forest, California.